Alfa Wasserman deal gives Theravance $63.5m plus royalties for velusetrag
This article was originally published in Scrip
Executive Summary
Theravance and the private Italian pharmaceutical group Alfa Wassermann have signed an exclusive development and commercialisation agreement worth up to $63.5 million plus royalties from sales for the US company's oral 5-HT4 agonist velusetrag (TD-5108) as a treatment for gastrointestinal motility disorders.